Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 4/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868188 | 0.92 | DCTPP1 (0.38) | DCTPP1ADORA2AADORA2BADORA1MET | |
| SCHEMBL4862734 | 0.90 | MAPT (0.44) | DCTPP1ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL4866480 | 0.86 | PARG (0.42) | GABRA5 | |
| SCHEMBL4862736 | 0.86 | PDE1A (0.40) | DCTPP1METPDE1APDE1BPDE1C | |
| SCHEMBL4868365 | 0.85 | ADORA3 (0.41) | DCTPP1ADORA2AADORA2BADORA1MAPT | |
| SCHEMBL4866971 | 0.81 | ADORA2B (0.44) | DCTPP1ADORA2AADORA2BADORA1NPC1 | |
| SCHEMBL4763446 | 0.81 | MAPT (0.52) | DCTPP1PDE1APDE1BPDE1CNPC1 | |
| SCHEMBL4763451 | 0.81 | MAPT (0.52) | DCTPP1PDE1APDE1BPDE1CNPC1 | |
| SCHEMBL4869916 | 0.81 | PARG (0.36) | GABRA5 | |
| SCHEMBL4866686 | 0.81 | MAPT (0.44) | DCTPP1ADORA2AADORA2BADORA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | DCTPP1 3735/4885ADORA2A 2/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.